<DOC>
	<DOC>NCT01181102</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.</brief_summary>
	<brief_title>A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Patients undergoing unilateral total knee arthroplasty Subjects with risks of hemorrhage Subjects with thromboembolic risks Subjects who weigh less than 40 kg Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>venus thromboembolism</keyword>
	<keyword>thrombosis</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>embolism and thrombosis</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>DU-176b</keyword>
	<keyword>Edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>total knee arthroplasty</keyword>
	<keyword>Enoxaparin sodium</keyword>
</DOC>